ABSTRACT
Management of Myeloproliferative Diseases in Senior Patients D. Wolf and R. Stauder Department of Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
Diagnosis and Classification of Myeloproliferative Disorders Myeloproliferative disorders (MPD) are relatively rare chronic hematologic malignancies that include the classic MPD: the Philadelphia chromosome (PH)-negative essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV) and Philadelphia chromosomepositive chronic myelogenous leukemia (CML). Atypical MPD include molecularly defined platelet-derived growth factor (PDGFR) A-rearranged eosinophilic/mast cell disorders; PDGFR B-rearranged eosinophilic disorders; systemic mastocytosis associated with c-kit mutation; 8p11 myeloproliferative syndrome; and juvenile myelomonocytic leukemia with recurrent mutations of RAS.
